Advertisement

Topics

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Company Profile

02:10 EDT 19th July 2018 | BioPortfolio


News Articles [2811 Associated News Articles listed on BioPortfolio]

New Bluebird data show promising benefits for gene therapy, if they last

New versions of Bluebird Bio's gene therapy for inherited blood disorders yielded significant benefits for patients, according to updated results from ongoing clinical trials.

BRIEF—bluebird bio names Alison Finger as CCO

US biotech bluebird bio, a clinical-stage company committed to developing potentially transformative…

Bluebird bio details plans to file three blockbusters

Bluebird bio has announced an “aggressive” plan to file three potential blockbuster drugs with regulators over the next three years, including its CAR-T therapy. Cambridge, Massachusetts-based bl...

Celgene and bluebird bio Team Up in New Deal

Celgene and bluebird bio have inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen (BCMA) CAR-T therapy for relapsed/refractory multiple myeloma (rrMM).

Medigene-Partner Bluebird Bio zieht kräftig an: Starke Studiendaten beflügeln

Vielen Lesern kommt Bluebird Bio als Partner der deutschen Medigene bekannt vor. Wesentlich wichtiger als die Kooperation ist aktuell das Krebsimmuntherapie-Projekt bb2121 für Bluebird, welches zus.....

Bluebird Bio One Step Closer to its First Approved Drug

Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).

Spectacular results for bluebird's gene therapy in thalassemia

Patients with the rare blood disorders transfusion-dependent ?-thalassemia (TDT) have shown spectacular results in clinical trials of bluebird bio's gene therapy, raising hopes the treatment could be ...

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR candidates, raising their already huge deal to a massive $1.5Bn. In September 2016, Medigene and blu...

Drugs and Medications [36 Associated Drugs and Medications listed on BioPortfolio]

Letrozole [APP Pharmaceuticals, LLC]

These highlights do not include all the information needed to use Letrozole Tablets, USP safely and effectively. See full prescribing information for Letrozole Tablets, USP Letrozole Tablets, USPIniti...

Letrozole [Kremers Urban Pharmaceuticals Inc.]

These highlights do not include all the information needed to use letrozole tablets safely and effectively. See full prescribing information for letrozole tablets. LETROZOLE Tablets, USPInitial U.S. A...

Letrozole [Qualitest Pharmaceuticals]

These highlights do not include all the information needed to use Letrozole Tablets, USP safely and effectively. See full prescribing information for Letrozole Tablets, USP. Letrozole Tablets, USPInit...

Letrozole [Accord Healthcare Inc.]

These highlights do not include all the information needed to use letrozole tablets safely and effectively. See full prescribing information for letrozole tablets. Letrozole Tablets, USP Initial U.S...

Letrozole [Roxane Laboratories, Inc.]

These highlights do not include all the information needed to use Letrozole Tablets, USP safely and effectively. See full prescribing information for Letrozole Tablets, USP.

PubMed Articles [6187 Associated PubMed Articles listed on BioPortfolio]

Interactions of body temperature and nutritional status on hypothalamo-pituitary-adrenal axis activity in pre-thermoregulatory eastern bluebird chicks (Sialia sialis).

Early life experiences can affect the function of the hypothalamo-pituitary-adrenal (HPA) axis of vertebrates, with potential fitness consequences later in life. In altricial species, for example, var...

Interpretation of the Results of the MINDACT Study and Consequent Recommendations in the Updated ASCO Clinical Practice Guideline.

Ongoing Evaluation of Clinical Ethics Consultations as a Form of Continuous Quality Improvement.

Ongoing evaluation of a clinical ethics consultation service (ECS) allows for continuous quality improvement, a process-based, data-driven approach for improving the quality of a service. Evaluations ...

Imaging in juvenile idiopathic arthritis - international initiatives and ongoing work.

Imaging is increasingly being integrated into clinical practice to improve diagnosis, disease control and outcome in children with juvenile idiopathic arthritis. Over the last decades several internat...

Ongoing child welfare services: Understanding the relationship of worker and organizational characteristics to service provision.

Ongoing child welfare services are put in place after completion of the initial maltreatment investigation when there is a perceived need to mitigate the risk of future harm. The knowledge of how clin...

Clinical Trials [5486 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy

This is a multi-center, long-term safety and efficacy follow-up study for subjects with hemoglobinopathies (β-thalassemia or severe sickle cell disease) who have been treated with ex vivo...

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing statin treatment in a double-blind manner in comparison with placebo, in the manag...

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.

Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year. In Europe, manufacturers/marketing holders of these ...

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season

Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year. In Europe, manufacturers/marketing holders of these ...

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season

Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year. In Europe, manufacturers/marketing holders of these ...

Companies [2849 Associated Companies listed on BioPortfolio]

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

bluebird bio, Inc.

bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gen...

bluebird bio, Inc. 

Lifebank

Lifebank will offer its clients the most current, clinically proven procedures available for the cryogenic storage of umbilical cord blood (UCB).Lifebank will be an educational leader in the field of ...

Minnesota Applied Research Center

MARC is a fully equipped clinical research site able to provide a full range of research services. MARC staff are experienced at taking research ideas from conception to completion in a proficient, p...

More Information about "bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting" on BioPortfolio

We have published hundreds of bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting news stories on BioPortfolio along with dozens of bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Clinical Trials and PubMed Articles about bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Companies in our database. You can also find out about relevant bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record